ReviewFuture oncology (London, England)2025
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of pembrolizumab in the treatment of HER2-negative advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis of emerging clinical data.Frontiers in immunology · 2026Pooled it
- Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.Targeted oncology · 2026Article
- First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.Cancer science · 2026Article
- Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report.Journal of surgical case reports · 2026Article
- Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.medRxiv : the preprint server for health sciences · 2026Article
- Review
- Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.Frontiers in immunology · 2026Article
- Research progress in augmentation strategies for PD-1/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications.Frontiers in immunology · 2026Review
- Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era.Frontiers in immunology · 2026Review
- Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.IJU case reports · 2026Article
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system.Frontiers in medicine · 2026Article
- Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-Invasive Bladder Cancer.Oncology research and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, has become the new standard of care for previously untreated locally advanced or metastatic urothelial carcinoma. In the recently published phase III study, EV-302, EV and pembrolizumab demonstrated improved outcomes compared to platinum-based chemotherapy, including objective response rate, progression free survival, and an unprecedented median overall survival of 33.8 months (versus 15.9 months; hazard ratio for death 0.51; 95% confidence interval 0.43-0.61;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.